Out-of-Pocket Costs Now Make Up Nearly Half of Large Hospital Balances, New Cedar and Health Management Academy Report Finds

Patients’ share of large, slow-to-resolve medical balances rose to 49.3% in Q1 2026 from 37.5% a year earlier. Total balances increased by $16 million to $323 million, while the out-of-pocket portion rose by $44 million to $159 million, implying about $28 million shifted from insurers to patients; smaller bills’ out-of-pocket share was essentially unchanged. A report based on five health-system case studies says systems are expanding earlier screening, tailored assistance and payment plans to address underinsurance.

Analysis

The economically important signal is not simply rising patient cost share; it is that more of the marginal receivable is owed by households whose ability to pay is weaker and less predictable than an insurer’s. For providers, that can lengthen cash conversion and raise bad-debt and collection costs even if gross billings hold up. If affordability support improves collections, it may protect net revenue—but longer payment plans can improve eventual recovery while worsening near-term cash flow. Earlier financial screening could also preserve elective-care volumes by reducing bill shock and delayed treatment, a second-order benefit not captured by balance recovery alone.

The vendor opportunity is plausible but not yet proven. Cedar’s data and two platform-using systems in a five-system case-study sample create selection and promotional-bias risks; the report does not establish that software alone caused better outcomes or quantify ROI. The more durable need may be operational coordination across eligibility, charity care, billing and clinical access, which limits the value of a standalone technology purchase unless systems change workflows.

Near term, this is a watch item rather than a sector-wide earnings trigger. Over 1–3 months, look for provider commentary on self-pay collections, bad debt, days in accounts receivable and charity-care policy; over 6–18 months, sustained patient affordability pressure could constrain discretionary care and increase demand for revenue-cycle and patient-financing tools. The thesis weakens if provider metrics remain stable or tailored plans demonstrably lift collections without delaying care. Cedar’s report is not independent proof of either outcome.

Key Decisions for Investors

• Avoid trading hospital providers on this report alone. Track self-pay collection rates, bad-debt expense, days in accounts receivable, charity-care provisions and elective-volume commentary at upcoming earnings; deteriorating cash conversion alongside stable billings would be the more actionable negative signal.
• Treat Cedar and revenue-cycle technology providers as a diligence watchlist, not an immediate long. Verify customer retention, implementation costs, contract economics and independently measured lift in net collections before underwriting adoption-driven upside; the report supplies no quantified causal ROI.
• Monitor hospitals’ payment-plan expansion for a trade-off between lower ultimate write-offs and slower cash receipts. A rise in receivables aging or financing costs without improved collection yield would falsify the claim that affordability programs are financially accretive.
• Watch for evidence that cost exposure is reducing care access—especially elective procedures—rather than merely shifting payment timing. If providers report volume deferrals tied to affordability, reassess the outlook for exposed provider systems and related healthcare-services demand.